Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252238 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL181517 | 0.98 | — | — | |
| SCHEMBL181630 | 0.90 | — | — | |
| SCHEMBL11882788 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL1923256 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL3069140 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL434733 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL3072659 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| SCHEMBL10728151 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 | |
| Synthalin SCHEMBL336302 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1CYP1A2KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | claimed |
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2019-09-24 | — | — | US | claimed |
| US-9969773-B2 | Polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2018-05-15 | — | — | US | claimed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | claimed |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2017-01-19 | — | — | US | claimed |
| WO-2010098843-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY (US) | 2010-09-02 | — | — | WO | claimed |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2010-09-02 | — | — | US | claimed |
| EP-1200457-B1 | CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2004-08-25 | — | — | EP | claimed |
| US-6635621-B1 | Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity | NAEJA PHARMACEUTICAL INC. (CA) | 2003-10-21 | — | — | US | claimed |
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | claimed |
| JP-2002544121-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1200457-A2 | CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-05-02 | — | — | EP | claimed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | claimed |
| WO-2001009169-A2 | CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2001-02-08 | — | — | WO | claimed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | F12, RPS4Y1, NPY1R | SMN1; SMN2 3801/4885MEN1 826/4885CYP1A2 443/4885 |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | F12, RPS4Y1, NPY1R | SMN1; SMN2 3801/4885MEN1 826/4885CYP1A2 443/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | SMN1; SMN2 130/4885MEN1 822/4885CYP1A2 1072/4885 |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | SMN1; SMN2 3644/4885MEN1 2370/4885CYP1A2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.